Abstract

RESTREPO, César A  and  CASTANO, Jesús A. Efficacy and safety of high-dose atorvastatin in patients with stage 5 chronic kidney disease on peritoneal dialysis therapy. Rev. Colomb. Cardiol. [online]. 2014, vol.21, n.6, pp.382-391. ISSN 0120-5633.  https://doi.org/10.1016/j.rccar.2014.05.008.

Objective: To determine changes in lipid profile and safety of treatment with atorvastatin at high doses (greater than or equal to 40 mg/day) in patients with stage 5 chronic kidney disease. Patients, materials and methods: Patients with stage 5 chronic kidney disease in peritoneal dialysis therapy and hypercholesterolemia refractory to therapy with lovastatin at a dose of 40 mg daily and atorvastatin (less than 40 mg/day) that were assigned to atorvastatin therapy at high doses. Statistical analysis: A longitudinal study, retroprospective, correlational, single center with univariate and bivariate analysis. Results: Twenty met the inclusion criteria. Time with high-dose atorvastatin averaged 27 months. The average dose used 60.4 mg/day. The beneficial tendency to achieve therapeutic goals with time-varying was achieved in 65% of patients for total cholesterol, 50% LDL cholesterol, 40% non-HDL cholesterol and 45% for triglycerides. For variables LDL cholesterol and HDL cholesterol a statistically significant (p < 0.05) difference was found between the initial and final values. Twenty six complications were documented, none of them considered adverse events related to the administration of high-dose atorvastatin. Conclusions: In patients with stage 5 chronic kidney disease over 50 years, peritoneal dialysis therapy and hypercholesterolemia, high-dose atorvastatin achieved LDL levels get goals in 50% of patients without significant adverse events.

Keywords : Cholesterol; Statins; Hypercholesterolemia; Kidney.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )